Recon: Novo Nordisk's next-generation obesity therapy falters in diabetes study; Sun Pharma to acquire Checkpoint Therapeutics for $355M
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States